Anavex Life Sciences Corp (AVXL)

[falconer66a]

2023 yes. But interim fun points before.

CY 2023 [when falconer sees total Anavex success] seems like the back of the moon from here. I am rooting for positive findings on multiple clinical events between now and then which will serve to accelerate the passage of time.

Thank you. Important point. The end of 2023 is almost two years from now; after the many years we’ve already been waiting for Anavex and blarcamesine to be successes.

Yes, with regulatory approval of blarcamesine, some time in 2023 or 24, Anavex will be an incontrovertible success. But there will be smaller, intervening successes in the mean time. Sooner, blarcamesine may be approved for Rett. Sooner or later, successful trials data will be announced from both the Parkinson’s disease dementia (PDD) trial and big Alzheimer’s trial. Those data won’t bring any immediate blarcamesine approval. That “will take study.”

So far, “the market” has been unimpressed with the early and yet incomplete clinical results from Anavex. How many retail equity investors have ever heard of “Rett syndrome?” It’s successful treatment isn’t going to get any front-page articles in the New York Times. But when blarcamesine is clinically shown to fix either PDD or Alzheimer’s, even before the drug gets approved, it will be Big News.

I see new blarcamesine information appearing incrementally and periodically on the way to the end of 2023. With PDD and Alzheimer’s results, the AVXL share price will elevate.

With sales approval, Anavex becomes a revenue-generating corporate entity. But how long after that approval will it take for “the market” to accurately assess Anavex’s future annual revenue streams? With some degree of anticipatory jest an AVXL share price of $1249 has been bandied about as reasonable sometime in the future. 2024 or 2025? Gonna be interesting to see. For me, worth waiting for.